Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
10:11
EXCLUSIV E-TRENDS by NewsVibe. The ranking of trending economic topics over the past week / The proposal to reduce the down payment through the “Noua Casă” program and the sale of Black Sea Oil & Gas
10:09
Formula 1: Pierre Gasly and his family received 13,000 threats / The FIA will use artificial intelligence to identify those responsible
10:04
ECB keeps the deposit rate at 2.50% and warns that more expensive energy threatens prices and economic growth
09:49
Alphabet loses 500 billion dollars
09:38
The Pentagon is asking some European governments to avoid provocative statements toward Russia, according to a Reuters investigation
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
